4 [7] R. S. Wallis, M. S. Broder, J. Y. Wong, M. E. Hanson, and D. O. Beenhouwer, “Granulomatous infectious diseases associated with tumor necrosis factor antagonists,” Clinical Infectious Diseases, vol. 38, no. 9, pp. 1261–1265, 2004. [8] K. L. Winthrop, S. Yamashita, S. E. Beekmann, and P. M. Polgreen, “Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: case ﬁnding through the emerging infections network,” Clinical Infectious Diseases, vol. 46, no. 11, pp. 1738–1740, 2008. [9] K. L. Winthrop, E. Chang, S. Yamashita, M. F. Iademarco, and P. A. LoBue, “Nontuberculous mycobacteria infections and anti-tumor necrosis factor-α therapy,” Emerging Infectious Diseases, vol. 15, no. 10, pp. 1556–1561, 2009. [10] M. Toruner, E. V. Loftus Jr., W. S. Harmsen et al., “Risk factors for opportunistic infections in patients with inﬂammatory bowel disease,” Gastroenterology, vol. 134, no. 4, pp. 929–936, 2008. [11] J. C. Fallon, S. Patchett, C. Gulmann, and G. M. Murphy, “Mycobacterium marinum infection complicating Crohn’s disease, treated with inﬂiximab,” Clinical and Experimental Dermatology, vol. 33, no. 1, pp. 43–45, 2008. [12] C. J. Majoor, A. J. M. Schreurs, and G. Weers-Pothoﬀ, “Mycobacterium xenopi infection in an immunosuppressed patient with Crohn’s disease,” Thorax, vol. 59, no. 7, pp. 631– 632, 2004. [13] T. S. Breza Jr. and C. M. Magro, “Lichenoid and granulo- matous dermatitis associated with atypical mycobacterium infections,” Journal of Cutaneous Pathology, vol. 33, no. 7, pp. 512–515, 2006. [14] D. Elston, “Nontuberculous mycobacterial skin infections: recognition and management,” American Journal of Clinical Dermatology, vol. 10, no. 5, pp. 281–285, 2009. Case Reports in Medicine